

Curriculum Vitae

Gabriela Nora Cesarman-Maus M.D.

General Information

Date of birth: October 24th 1959

Nationality and Citizenship-Mexican

Medical Licensure- México 1986

Internal Medicine and Sub-Specialty Boards in Hematology/Oncology- México

ECFMG 1989

National Researcher's System (SIN): level II

Educational Background

MD 1986 Universidad Nacional Autonoma de México, (UNAM). Faculty of Medicine,

SS 1985 Department of Pathology. National Institute of Medical Sciences (Social Service Thesis: Reclassification of non-Hodgkins Lymphomas)

MS 1989 Internal Medicine Residency at the National Institute of Medical Sciences and Nutrition, NIH-Mexico

MSS 1994 Fellowship in Hematology and Oncology at the New York Hospital –Cornell Medical Center.

1992-1994 Post Doctoral Research Fellowship. Vascular Research Center. Dr. Katherine Hajjar's Laboratory. Cornell Medical Center. Characterization of Annexin 2. Susan J Murphy Scholar.

2005-2009 PhD in Ciencias Químico Biológicas at the Instituto Politécnico Nacional

Professional Positions Held

1980-1983 Teachers Assistant, Department of Embriology

1980-1981 Teachers Assistant. Department of Histology

1980-1981 Teachers Assistant in Nosology

2001 Chief Fellow. Hematology- Oncology Dept. NY Hospital-Cornell MedicalCenter

1994 - Hematology and Oncology Attending at the National Institute of Medical Sciences and Nutrition , NIH Mexico (INCMNSZ)

1994- Director, Coagulation Clinical and Research Laboratory. INCMNSZ

1995-1996 Head Hemostasis and Thrombosis section for the Mexican Hematology Association (AMEH)

1994 - Private Practice

2001 Head Scientific Committee for the XVII International Congress CLAHT (Latin-American Cooperative Group on Thrombosis and Hemostasis) Meeting in México City.

2001-2003 California Health Advisor for the Mexican Ministry of Foreign Affairs

2003- Post-Doctoral Research Fellow, Department of Cell and Developmental Biology. Weill Medical Center of Cornell University

2007-12 Coordinator for benign Hematology NCI, Mexico

2007- 2016 Head, Cancer and Thrombosis Service, Department of Hematology , NCI, Mexico.

2009-12 Coordinator; Catheter and Thrombosis Clinic . NCI, Mexico
 2011-13 Scientific Chair.: Asociación Mexicana de Hematología.
 2012 - Tutor Post-graduate Doctorate Program. (Veterinary Medicine, UNAM)
 Tutor in Post-graduate Studies for Masters and PhD in Medical Sciences.
 National Autonomous University (UNAM).
 2013. Tutor, Facultad de Química, Instituto Politécnico Nacional-
 2013- Representante de FUNSALUD/AMEH
 2013- Professor in Hematology: Faculty of Medicine UNAM (3rd year)
 2015- Research Coordinator, Department of Hematology, NCI.Mexico
 2015- Founding member "Sociedad Mexicana de Trombosis y Hemostasia
 SOMETH
 2016 -2018 Delegate for SOMETH as Board member of Thrombosis and Hemostasis
 Societies of North America (THSNA)"
 2016. Scientific Committee member SOMETH
 2015- Founding member "Colegio Mexicano para la Investigación del Cáncer"
 2017 Delegate for CLAHT in Mexico.

Professional Thesis Directed

Masters

1996 Armando Villegas. UNAM. Masters in Science. Anticoagulant
 monitoring in patients with antiphospholipid syndrome.
 2002 Carlos Cantu. UNAM. Masters in Science Folic Acid Deficiency as a cause
 for Cerebral Vascular Thrombosis.

Graduate Chemistry Thesis

1995 Raul Trejo. Faculty of Chemistry. UNAM. Activated platelet rich
 plasma supernatant for treatment of diabetic ulcers.
 1997 Jessica Cuevas Manzo. QFB. Faculty of Bioanalysis. Universidad
 Veracruzana. Activated Protein C in prothrombotic assays for the Clinical
 Laboratory.
 1998 Guadalupe Montiel. Faculty of Chemistry, UNAM. Prevalence of Factor V
 Leiden in Public Hospitals, Mestizo Population.
 2000 Carlos Virgen. Universidad Veracruzana. Coagulation Parameters in
 Lupus Patients
 2016 Mara Nuñez. Instituto Nacional de Pediatría. (will finish in 2018)

Fellowship

1995 Carlos Rosillo. INCMNSZ. Lack of APCR and factor V Leiden Mutation as a
 causative Factor for Splenic Vein Thrombosis.

Board Certification in Mexico

Internal Medicine
 Hematology

Professional Memberships

ASH
 ASCO
 CLAHT (Latin American Group on Hemostasis and Thrombosis)
 AMEH (Asociación Mexicana para el Estudio de la Hematología)
 HTRS

Anticoagulation Forum
THSNA

Joural Ad-Hoc Reviewer and Others

1995- Rev. Invest.Clin.and Archives of Medical Research
1995 - Scientific Committee Member. Premios Marcos y Cela Maus
for Masters and PHD Thesis in Medicine and SciencesUNAM
2001 Consultive Committee for the ISTH, Paris 2001
2012- Applied Thrombosis and Haemostasis
2015 - Molecular Cáncer
2018 . Frontiers in Medicine Research Topics
2018 JTH

Honors and Awards

Second Place Generation 1979-85. Faculty of Medicine. UNAM
1993 Chief Resident. Department of Haematology Oncology. New.York Hospital.
Cornell Medical Center.
1992-1994 Susan Murphy Fellow. Cornell Medical Center.

Dr. Luis Sanchez Medal Award. Awarded by the Asociación Mexicana de Hematología

- 2012 First Place for clinical research article. (Jury from Chile)
- 2013 Third Place for basic research article (Jury from Argentina)
- 2016 Third Place for basic research article (Jury from Venezuela)
- 2018 Second and Third place for clinical research article (Jury from Argentina)

Languages

Spanish, English. Read French, Italian, Idish.

Bibliography

1. van Es N, Hisada Y, Di Nisio M, **Cesarman G**, Kleinjan A, Mahé I, Otten HM, Kamphuisen PW, Berckmans RJ, Büller HR, Mackman N, Nieuwland R. Extracellular vesicles exposing tissue factor for the prediction of venous thromboembolism in patients with cancer: A prospective cohort study. *Thromb Res.* 2018 Jun;166:54-59. doi: 10.1016/j.thromres.2018.04.009. Epub 2018 Apr 10.
2. Sánchez D, **Cesarman-Maus G**, Amador-Molina A, Lizano M. Oncolytic Viruses for Canine Cancer Treatment.. *Cancers (Basel).* 2018 Oct 27;10(11). pii: E404. doi: 10.3390/cancers10110404
3. Pabinger I, van Es N, Heinze G, Posch F, Riedl J, Reitter EM, Di Nisio M, Cesarman-Maus G, Kraaijpoel N, Zielinski CC, Büller HR, Ay C. A clinical prediction model for

- cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. *Lancet Haematol.* 2018 Jun 7. pii: S2352-3026(18)30063-2. doi: 10.1016/S2352-3026(18)30063-2
4. van Es N, Di Nisio M, Cesarman G, Kleinjan A, Otten HM, Mahé I, Wilts IT, Twint DC, Porreca E, Arrieta O, Stépanian A, Smit K, De Tursi M, Bleker SM, Bossuyt PM, Nieuwland R, Kamphuisen, PW, Büller HR. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study *Haematologica.* 2017 Sep;102(9):1494-1501.
 4. Volkow P, Cesarman-Maus G, Garciadiego-Fossas P, Rojas-Marin E, Cornejo-Juárez P. Clinical characteristics, predictors of immune reconstitution inflammatory syndrome and long-term prognosis in patients with Kaposi sarcoma. *AIDS Res Ther.* 2017 May 30;14(1):30.
 5. Cesarman-Maus G, Ruiz-Argüelles GJ. News in the Indications of Direct Oral Anticoagulants According to the American College of Chest Physicians 2016 Guidelines. *Curr Drug Metab.* 2017;18(7):651-656.
 6. Fonseca R, Cesarman-Maus G, Braggio E. Personalizing the Use of Circulating Microparticle-Associated Tissue Factor as a Biomarker for Recurrent Thrombosis in Patients with Cancer. *J Clin Oncol.* 2017 Jul 1;35(19):2217-2218. Sánchez D, Pelayo R, Medina LA, Vadillo E, Sánchez R, Núñez L, Cesarman-Maus G, Sarmiento-Silva RE. Newcastle Disease Virus: Potential Therapeutic Application for Human and Canine Lymphoma. *Viruses.* 2015 Dec 23;8(1). pii: E3. doi: 10.3390/v8010003
 7. Cabrera-Fuentes HA, Alba-Alba C, Aragonés J, Bernhagen J, Boisvert WA, Bøtker HE, Cesarman-Maus G, Fleming I, Garcia-Dorado D, Lecour S, Liehn E, Marber MS, Marina N, Mayr M, Perez-Mendez O, Miura T, Ruiz-Meana M, Salinas-Estefanon EM, Ong SB, Schnittler HJ, Sanchez-Vega JT, Sumoza-Toledo A, Vogel CW, Yarullina D, Yellon DM, Preissner KT, Hausenloy DJ. Meeting report from the 2nd International Symposium on New Frontiers in Cardiovascular Research. Protecting the cardiovascular system from ischemia: between bench and bedside. *Basic Res Cardiol.* 2016 Jan;111(1):7. doi: 10.1007/s00395-015-0527-0. Epub 2015 Dec 14.
 8. Meillón-García LA, Hernández-Zamora E, Montiel-Manzano G, Zavala-Hernández C, Ramírez-San Juan E, Cesarman-Maus G, Reyes-Maldonado E. Anticoagulant proteins in a population of Mexican mestizo donors. *Ann Vasc*

- Surg. 2015 Feb;29(2):222-6. doi: 10.1016/j.avsg.2014.09.023. Epub 2014 Nov 24.
9. Cesarman-Maus G, Eteban Braggio, Carmen Lome-Maldonado, Ana Lilia Gómez-Leyte, Rafael Fonseca. Absence of tissue factor is characteristic of lymphoid malignancies of both T- and B-cell origin. *Thrombosis Research* 2014 133 (4), 606–609
 10. Cesarman-Maus G, Meillón L, Volkow P, Vargas-Ruiz AG, Cornejo P, López-Navarro O, Moreno MC, Coronel O, García-Fernandez L, Ochoa-Carrillo FJ, Siñani M, Baz P, Izaguirre R. Tratamiento de Cáncer y Trombosis: enfoque práctico. *Rev Invest Clin.* 2013 Mar-Apr;65(2):174-82.
 11. Cesarman-Maus G, Villa R, Peter Kubisz, Monica Gonzalez-Ramirez, G. El síndrome de Plaquetas Pegajosas.(SPP) *Revista de Hematología.* 2013; 14 149-153
 12. Cesarman-Maus G, Eteban Braggio, Rafael Fonseca. Tissue factor and hematological neoplasias. *Blood* 2012, April 13 Re: Blood-2011-06-317685,
 13. Hedhli N, Falcone D, Huang B, Cesarman-Maus G. The Annexin A2/S100A10 System in health and disease: emerging paradigms. *J. Biomed and Biotechnol* 2012, (406273) pp:1-13
 14. Gabriela Cesarman-Maus, Esteban Braggio, Hector Maldonado, Rafael Fonseca. Absence of tissue factor expression by neoplastic plasma cells in multiple myeloma. *Leukemia* 2012, doi:10.1038/leu.2012.43 pag 1-4
 15. Gabriela Cesarman-Maus Esteban Braggio, Rafael Fonseca. Thrombosis in multiple myeloma. *Hematology* 2012. Vol 17, (suppl 1) pp. S1, S177 p.p 1-3
 16. Gabriela Cesarman-Maus. Myths and reality of Sticky platelet Syndrome. *Rev Hematol Mex* 2011; 12(2): 55-56.
 17. Gabriela Cesarman-Maus MD, PhD, Carlos Cantú-Brito MD, PhD, Fernando Barinagarrementeria MD, Rosario Villa, Elba Reyes PhD, Jorge Sanchez-Guerrero MD, Katherine A Hajjar MD, Ethel Garcia Latorre PhD. Autoantibodies against the Fibrinolytic Receptor, Annexin A2, in Cerebral Venous Thrombosis. *Stroke.* Adoi: 10.1161/Stroke.AHA.110.592121 Feb 2011, 501-503.
 18. Escudero PM, y cols incluyendo Cesarman-Maus G. Parámetros de práctica clínica basados en evidencia en tromboprolifaxis. *Trombosis y Cáncer.* GAMO 2009, 08 (sup 4).

19. Cesarman-Maus G, Rios-Luna P, Deora-Kumar A et al. Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. *Blood*, 2006 Jun 1;107(11):4375-82.
20. Cesarman-Maus G, Hajjar KA. Annexin checks in - Response to Waisman. *Br.J Haematol*. 2005 Nov;131(4)
21. Cesarman-Maus G. Hajjar K. Molecular Mechanisms of Fibrinolysis. *Br.J.Haematol* 2005 May;129(3):307-21
22. Cesarman G. The Consular Program for Mexican Communities Abroad as a Source of Outreach for Health Workers. *J Transcult Nurs* 2003 14: 272-275.
23. Montiel-Manzano G, de la Pena-Diaz A, Majluf-Cruz A, Cesarman-Maus G, Corona-de la Pena N, Cruz-Cruz D, Gaminio E, Martinez-Murillo C, Mayagoitia T, Miranda-Peralta E, Poblete T, Quintana-Martinez S, Ramirez Razo D, Ruiz de Chavez-Ochoa A, Reyes-Nunez VA, Salazar R, Vicencio-Santiago GV, Villa R. Evaluación Nacional del diagnóstico de la resistencia a la proteína C activada *Rev Invest Clin*. 2003 May-Jun;55(3):358-69.
24. Gomez-Perez FJ, Aguilar-Salinas CA, Vazquez-Chavez C, Fanghanel-Salmon G, Gallegos-Martinez J, Gomez-Diaz RA, Salinas-Orozco S, Chavira-Lopez IJ, Sanchez-Reyes L, Torres-Acosta EM, Tamez R, Lopez A, Guillen LE, Cesarman G. Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d: effects on the very-low-density and high-density lipoprotein particle distribution. *Metabolism*. 2002 Jan;51(1):44-51.
25. Cesarman.G Anti-Annexin antibodies and Antiphospholipid / cofactor Syndrome. *Memorias del XVII Congreso CLAHT*. 2002,
26. Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KA.. Annexin II and bleeding in acute promyelocytic leukemia. *N Engl J Med* 1999 Apr 1;340(13):994- 1001
27. Raffi S, Coleman M, Kaufmann T, Cesarman G, Papish SW, Bernhart B, Gaynor M, Reisman AM. CODBLAM IV chemotherapy for large cell lymphoma: sequential use of infusional vincristine and bleomycin and "high dose" consolidation. *Am J Clin Oncol* 1997 Feb;20(1):90-6
28. Rojas G, Alberu J, Bordes-Aznar J, Quintanilla-Martinez L, Lome-Maldonado MC, Cesarman G, Angeles-Angeles A, Correa-Rotter Clinical and pathological characterization of posttransplantation lymphoproliferative disorders in kidney

- transplant recipients: single institution experience. R. Transplant Proc 1996 Dec;28(6):3317-20
29. Cesarman GM, Guevara CA, Hajjar KA. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA dependent plasminogen activation. J Biol Chem 1994 Aug 19;269(33):21198-203
 30. Cesarman G, Cesarman E, Lagos G. Prevention and treatment of traveler's diarrhea. N Engl J Med 1993 Nov
 31. Herrera MF, Lozano-Salazar RR, Bezaury P, Cesarman G, Hernandez G, Sanchez SA, Velazquez A, Lopez-Karpovitch X. Laparoscopic splenectomy in autoimmune thrombocytopenic purpura. Rev Invest Clin. 1998 Mar-Apr;50(2):127-32. Spanish.
 32. Cesarman G. Agentes Fibrinolíticos. Mecanismos de Acción, Beneficios y Desventajas. Programa Educativo AMEH, 1996
 33. Cesarman G. Enfermedad de Von Willebrand. Programa Educativo AMEH, 1996
 34. Cesarman G. Update on the Fibrinolytic, protein C and S Systems. Revista de Investigación Clínica. 1995 April 47 (1): 226-31 Spanish
 35. Rao PH, Cesarman G, Coleman M, Acaron S, Verma RS. Cytogenetic evidence for extramedullary blast crisis with t(8;13),(q11;p11) in chronic myelomonocytic leukemia. Acta Haematol 1992;88(4):201-04
 36. Sanchez-Guerrero J, Cesarman G, Alarcon-Segovia D. Massive pulmonary hemorrhage in mixed connective tissue diseases. J Rheumatol 1989 Aug;16(8):1132-4
 37. Guevara L, Cesarman G. Case Record. A 30-year-old woman with diabetes mellitus, generalized cutaneous hyperpigmentation and congestive heart failure. Rev Invest Clin 1986 Oct-Dec;38(4):429-33
 38. Cesarman. G. Angeles Angeles A. Pathological reclassification of non-Hodgkin's lymphomas with the New Working Formulation. A retrospective review of clinical characteristics and outcomes. Archivos UNAM marzo1986.
 39. A M Silvia G Cesarman, I F Veja, L Mijares , A Cacho, M Pérez. "Cáncer se vejiga avanzado" Advanced Bladder Cancer. Gamo Vol.5 Núm. 6 nov-dic 2006 pag.201-204

40. Cesarman-Maus Gabriela "Actualidades en los Sistemas Fibrinolítico y de Proteínas C y S. La Revista de Investigación Científica. Suplemento 1 Vol. 47 Abril, 1995, pag. 16-19

Chapters in Books.

1. Cesarman G. "Linfomas gastrointestinales primarios" Bandera J, Cañedo S, Olivera M y Schmulson M, Eds. Masson. Progresos en gastroenterología. 1a edición 2001. pp143/150.
2. Alberu J, Cesarman G et al. Clasificación clínica e histología de lesiones linfoproliferativas post-transplante. J. Alberú. L Soto Eds. Enfermedades Infecciosas en receptores de transplantes. Mc Graw Hill Interamericana, 1998.
3. Cesarman G, Montiel-Manzano G. Anticoagulante Lupico. Manual de Laboratorio Clínico, 2005 .
4. Kleinjan A, Bossuyt PM, Cesarman-Maus G et al. Prediction of venous thromboembolism in cancer patients by tissue factor dependent microparticle coagulant activity, biomarkers and clinical score. Eds. Ankie Kleinjan Venous Thrombosis in Cancer Patients. Prediction, Diagnosis and Management. 2013. Cap 7. pp 85-95
5. Cesarman G, Izaquirre R, Meillón L, y cols. Oncoguías INCAN 2011. Guías de Cáncer y Trombosis.
6. Silvia Rivas, Cesarman G y cols. Oncoguías INCAN 2011. Guías de Linfomas.